Dr Elisa Agostinetto meets Dr Guilherme Nader Marta
In this interview, we bring together two ASCO award winners, both working at the Institut Jules Bordet in Brussels, to discuss their winning abstracts in front of the camera.
Dr Agostinetto presents exploratory results from the AURORA program, an international initiative focused on studying advanced breast cancer through multi-omics profiling of paired primary tumours and metastases. The presentation at ASCO highlights the findings from AURORA patients who were treated with first-line CDK4/6 inhibitors in combination with endocrine therapy.
Dr Guilherme Nader Marta discusses the preliminary results of the PRISMA study, which aims to evaluate PSMA expression in patients with metastatic triple-negative breast cancer using positron-emission tomography/computed tomography. The study focuses on assessing the feasibility of PSMA-targeted radioligand therapy for triple-negative breast cancer, as early studies indicate high PSMA expression in this subtype based on immunohistochemistry.
Furthermore, CDK4/6 inhibitors in combination with endocrine therapy have become the standard of care in the treatment of estrogen receptor-positive, HER2-negative advanced breast cancer. Dr Agostinetto presents the results of the NeoRHEA phase II, single-arm study, which investigated the use of palbociclib plus endocrine therapy as neoadjuvant therapy. The study aimed to identify baseline biomarkers that could predict a lack of response to this treatment regimen.
With the educational support of:
